Stereotactic Radiosurgery (SRS) at 20-22 Gy is the Preferred Treatment for Two Small Brain Metastases from Ewing Sarcoma
For a patient with metastatic Ewing sarcoma presenting with two small brain lesions, stereotactic radiosurgery (SRS) alone should be used rather than whole-brain radiotherapy (WBRT), with a recommended dose of 20-22 Gy per lesion in a single fraction.
Treatment Modality: SRS Over WBRT
The most recent high-quality guidelines strongly support SRS for limited brain metastases (1-4 lesions). SRS alone should be offered to patients with one to two brain metastases 1. This recommendation is based on evidence showing that while WBRT provides better intracranial control, it comes at the significant cost of neurocognitive decline and reduced quality of life—outcomes that directly impact morbidity 1, 2.
The EANO-ESMO guidelines (2021) reinforce that SRS has become the standard of care for limited brain metastases, noting that WBRT after SRS improved local and distant brain control but not overall survival, and was associated with detrimental effects on neurocognitive function 2.
Key Rationale:
- SRS provides excellent local control (96-99% at one year) with minimal neurotoxicity
- WBRT does not improve survival in patients with limited metastases
- Cognitive preservation is critical for quality of life
- Close surveillance with salvage SRS for new lesions is a viable strategy
Dosing Recommendations
The optimal SRS dose for small brain metastases (≤2 cm) is 20-22 Gy in a single fraction.
Evidence-Based Dosing:
The most recent comparative study (2026) demonstrated that 22 Gy was associated with significantly higher 1-year local control rates (96.3%) compared to 20 Gy (90.1%), with an adjusted odds ratio of 3.04 3. However, higher doses also increased radiation necrosis risk.
Historical data supports 20 Gy as the standard dose, with one large series showing 99% local control when combining 20 Gy SRS with WBRT, though WBRT is no longer recommended upfront 4. The German DEGRO guidelines recommend 20 Gy as a reasonable choice that balances local control against radionecrosis risk 5.
Specific Dosing Algorithm:
- Lesions <1 cm: Consider 22-24 Gy
- Lesions 1-2 cm: Use 20-22 Gy (optimal range)
- Lesions 2-3 cm: Use 18-20 Gy or consider fractionated SRS
- Lesions >3 cm: Use fractionated SRS (27 Gy in 3 fractions or 30 Gy in 5 fractions) 2
Technical Considerations
Use minimal margins: GTV-CTV margin should be 0-1 mm, and CTV-PTV margin 0-2 mm depending on your stereotactic system 5. This precision minimizes dose to normal brain while maintaining tumor coverage.
Common Pitfalls to Avoid
Do not add upfront WBRT: While it reduces distant brain failure, it does not improve survival and significantly impairs cognition 1, 2
Do not exceed 22 Gy for lesions >1 cm: Doses >20 Gy showed no improvement in local control but increased Grade 3-4 neurotoxicity (5.9% vs 1.9%) 4
Monitor for radiation necrosis: Both dose and tumor volume independently predict necrosis risk. Larger volumes require dose reduction 3
Plan for surveillance: Close MRI follow-up (typically every 2-3 months initially) is essential, as salvage SRS for new lesions is highly effective
Special Considerations for Ewing Sarcoma
While Ewing sarcoma is traditionally considered radiosensitive, brain metastases from this histology are rare and not specifically addressed in major guidelines. However, the general principles for brain metastases apply. The aggressive nature of Ewing sarcoma 6, 7 makes local control critical, supporting the use of adequate SRS doses (20-22 Gy range) rather than lower doses.
Coordinate with medical oncology regarding systemic therapy timing, as modern targeted and immunotherapies may have CNS activity and could be integrated with SRS 8.